Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
Ahead of Acadia Pharmaceuticals Inc’s (NASDAQ:ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag…
55 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
5 Biotech Stocks To Watch During The Week Of June 13
Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves.
Here's a compilation of five stocks that should be on your radar in the week of June 13:
1. Novavax
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month, bringing the total for the year to 15. This compares to the 24 NMEs the Food and Drug Administration approved by May 2021.
ACADIA Pharmaceuticals’s Return On Capital Employed Insights
ACADIA Pharmaceuticals (NASDAQ:ACAD) brought in sales totaling $115.47 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 162.35%, resulting in a loss of $113.06 million.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Analysts Say Acadia’s Negative Pain Data Increases Focus On Pimavanserin For Alzheimer’s-Related Psychosis
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain…
What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:
Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $27
Mizuho analyst Vamil Divan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $28 to $27.
23 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss.